106 related articles for article (PubMed ID: 8578256)
1. T-antigens in primary non-invasive and superficially invasive human urinary bladder tumors: the correlation to tumor recurrence and tumor progression. A mini-review.
Langkilde NC
Scand J Urol Nephrol Suppl; 1995; 172():45-9. PubMed ID: 8578256
[TBL] [Abstract][Full Text] [Related]
2. Detection of Tn antigen with Vicia villosa agglutinin in urinary bladder cancer: its relevance to the patient's clinical course.
Nishiyama T; Matsumoto Y; Watanabe H; Fujiwara M; Sato S
J Natl Cancer Inst; 1987 Jun; 78(6):1113-8. PubMed ID: 3295352
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder.
Allard P; Fradet Y; Têtu B; Bernard P
Clin Cancer Res; 1995 Oct; 1(10):1195-202. PubMed ID: 9815912
[TBL] [Abstract][Full Text] [Related]
5. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
6. Blood group antigens in transitional cell tumours of the urinary bladder. An immunohistochemical study.
Juhl BR
Dan Med Bull; 1994 Feb; 41(1):1-11. PubMed ID: 8187557
[TBL] [Abstract][Full Text] [Related]
7. [The study of cell surface antigens in bladder tumors: ABH-isoantigen and Thomsen-Friedenreich antigen].
Kobayashi H
Hinyokika Kiyo; 1987 Apr; 33(4):535-44. PubMed ID: 3618425
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
9. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
10. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer.
Li M; Song T; Yin ZF; Na YQ
Chin Med J (Engl); 2007 Mar; 120(6):469-73. PubMed ID: 17439739
[TBL] [Abstract][Full Text] [Related]
11. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
12. Studies on the expression of T-(Gal beta (1-3) GalNAc alpha 1-O-R) and T-like antigens in normal and pathologic human and rat urothelium.
Langkilde NC
Scand J Urol Nephrol Suppl; 1995; 176():7-46. PubMed ID: 8771266
[No Abstract] [Full Text] [Related]
13. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
14. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
15. [Study of the Thomsen-Friedenreich antigen in bladder tumors].
Fukatsu H; Yamada H; Nonomura H; Miyagawa Y; Waki M; Hatano Y; Hiraiwa S; Muramatsu T; Nishikawa E; Yamada Y
Hinyokika Kiyo; 1988 Feb; 34(2):260-7. PubMed ID: 3376818
[TBL] [Abstract][Full Text] [Related]
16. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
[TBL] [Abstract][Full Text] [Related]
18. Changing expression of ABH blood group and cryptic T-antigens of noninvasive and superficially invasive papillary transitional cell carcinoma of the bladder from initial occurrence to malignant progression.
Yamada T; Fukui I; Yokokawa M; Oshima H
Cancer; 1988 Feb; 61(4):721-6. PubMed ID: 3338034
[TBL] [Abstract][Full Text] [Related]
19. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H
Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341
[TBL] [Abstract][Full Text] [Related]
20. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma.
Krüger S; Mahnken A; Kausch I; Feller AC
Eur Urol; 2005 Apr; 47(4):463-7. PubMed ID: 15774242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
